Crossmark

The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France

Crossref DOI link: https://doi.org/10.1007/s13300-017-0321-0

Published Online: 2017-11-13

Published Print: 2018-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Basson, Mickael

Ntais, Dionysios

Ayyub, Ruba

Wright, Donna

Lowin, Julia

Chartier, Florence

Roze, Stéphane

Norrbacka, Kirsi
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2017-11-13
More Information

Article History

Received: 14 July 2017

First Online: 13 November 2017